A new era in atherosclerosis drug discovery

Expert Review of Cardiovascular Therapy

Volumn 2, Issue 5, 2004, Pages 633-636

  Meng, Charles Q ^a  

^a AtheroGenics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ANTIINFLAMMATORY AGENT; ATORVASTATIN; AUTACOID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARDIOVASCULAR AGENT; CD40 ANTIGEN; CHOLESTEROL; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; PLACEBO; PRAVASTATIN; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROMA; ATHEROSCLEROSIS; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; EDITORIAL; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; PRESCRIPTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; HUMANS; HYPERCHOLESTEROLEMIA; INFLAMMATION MEDIATORS;

EID: 4544253571     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.2.5.633     Document Type: Editorial

References (26)

1. Brown M, Goldstein JL. How LDL receptors influence cholesterol and atherosclerosis. Sci. Am. 251, 58-66 (1984).
2. Castelli WP. Lipids, risk factors and ischemic heart disease. Atherosclerosis 124(Suppl.), S1-S9 (1996).
3. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340, 115-126 (1999).
4. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Ann. Rev. Biochem. 52, 223-261 (1983).
5. Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nature Med. 8, 1235-1242 (2002).
6. Steinbrechner UP, Parthasarathy S, Leake DS et al. Modification of low-density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low-density lipoprotein phospholipids. Proc. Natl Acad. Sci. USA 81, 3883-3887 (1984).
7. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 105, 1135-1143 (2002).
8. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nature Med. 8, 1257-1262 (2002).
9. Heart Protection Study Collaboration Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360, 7-22 (2002).
10. Topol EJ. Intensive statin therapy: a sea change in cardiovascular prevention. N. Engl. J. Med. 350, 1562-1564 (2004).
11. Suckling KE. Cholesterol and plasma lipid modifying patents. Exp. Opin. Ther. Patents 8(11), 1415-1424 (1998).
12. Pentikäinen MO, Öörni K, Ala-Korpela M et al. Modified LDL - trigger of atherosclerosis and inflammation in the arterial intima. J. Intern. Med. 247, 359-370 (2000).
13. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. J. Am. Med. Assoc. 291, 1071-1080 (2004).
14. Cannon CP, Braunwald E, McCabe CH et al. Comparison of intensive and moderate lipid lowering with statins following acute coronary syndrome. N. Engl. J. Med 350, 1495-1504 (2004).
15. Auer J, Berent R, Weber T, Eber B. Clinical significance of pleiotropic effects of statins: lipid reduction and beyond. Curr. Med. Chem. 9, 1831-1850 (2002).
16. Cybulsky MI, Iiyama Y, Li H et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J. Clin. Invest. 107, 1255-1262 (2001).
17. Peter K, Weirich U, Nordt TK et al. Soluble vascular cell adhesion molecule (VCAM)-1 as a potential marker of atherosclerosis. Thromb. Haemost. 82(Suppl.), 38-43 (1999).
18. Ylä-Herttuala S, Lipton BA, Rosenfeld ME et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc. Natl Acad. Sci. USA 88, 5252-5256 (1991).
19. Cushing SD, Berliner JA, Valente AJ et al. Minimally modified low-density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc. Natl Acad. Sci. USA 87, 5134-5138 (1990).
20. Gu L, Okada Y, Clinton SK et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low-density lipoprotein receptor-deficient mice. Mol. Cell 2, 275-281 (1998).
21. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107, 363-369 (2003).
22. Ridker PM, Rifai N, Clearfield M et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 344, 1959-1965 (2001).
23. Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350, 1387-1397 (2004).
24. Reinhart WH. Fibrinogen - marker or mediator of vascular disease? Vasc. Med. 8, 211-216 (2003).
25. Mizia-Stec K, Zahorska-Markiewicz B, Mandecki T et al. Hyperlipidemias and serum cytokines in patients with coronary artery disease. Acta Cardiol. 58, 9-15 (2003).
26. Shishehbor MH, Hazen SL. Inflammatory and oxidative markers in atherosclerosis: relationship to outcome. Curr. Atheroscler. Rep. 6, 243-250 (2004).